Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Infliximab vs placebo

Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.73 [0.63, 0.84]
2 studies · 408 participants
Moderate

Infliximab combined with purine analogues vs purine analogues

Clinical relapse · Participants with Crohn's disease in remission

Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.2 [0.1, 0.42]
1 study · 115 participants
Moderate